Nonfiction 14

Essentials of SGLT2 Inhibitors in Diabetes by Miles Fisher, Gerard McKay

By Miles Fisher, Gerard McKay

Written by means of specialists within the box, this scientific guide explores the unconventional SGLT2 drug classification for the therapy of diabetes. This booklet comprises evidence-based instructions, significant medical trials, and a dialogue of treatment plans presently to be had, in addition to these at the moment in improvement. Essentials of SGLT2 Inhibitors is a perfect academic source for busy doctors who have to remain up to date with diabetes therapy advances with the intention to give you the absolute best medical deal with their patients.

Show description

Read Online or Download Essentials of SGLT2 Inhibitors in Diabetes PDF

Similar nonfiction_14 books

Defoe’s Review 1704-13, Volume 9

Defoe's overview performed an important function within the start of the trendy press. It used to be no longer a newspaper dealing in proof yet a magazine of opinion and dialogue. This sequence is the 1st entire scholarly variation of the total run of Defoe's overview. it truly is totally reset and supported through complete editorial equipment.

Plant secondary metabolites Volume 3, Their roles in stress ecophysiology

This 3rd e-book within the three-volume Plant Secondary Metabolites examines the connection among environmental pressure and the body structure of vegetation, resulting in stimulation of secondary metabolites. numerous stressors are mentioned, together with plant and soil interfaces, altering weather parts, crucial plant foodstuff, pest bugs, plant pathogens and microrganisms, and extra.

Knowledge Building and Regulation in Computer-Supported Collaborative Learning

This publication proposes and validates a data stream method of reading wisdom co-construction and predicting staff functionality within the context of collaborative studying. moreover, it highlights the significance of socially shared law in collaborative studying, and illustrates intimately the way it may be analyzed and promoted.

Additional info for Essentials of SGLT2 Inhibitors in Diabetes

Example text

74 kg, as compared to weight gain with placebo) [10]. Similar findings have been reported for canagliflozin and empagliflozin, with weight loss in short-term studies when using them as first-line, as well as weight loss when added to drugs that are known to cause weight gain, including insulin. Weight loss benefits appear to be sustained [10]. Initial weight loss for SGLT2 inhibitors may be due to the osmotic diuretic effect of treatment. However, sustained weight loss over the subsequent weeks is a consequence of caloric loss due to glycosuria.

Position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2012;35:1364–79. 3. Inzucchi SE, Bergenstal RM, Buse JB, Dimant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9. 4. Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, et al.

Int J Clin Pract. 2013;67:1267–82. 22. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycaemic control with metformin plus sulphonylurea – a 52-week randomised trial. Diabetes Care. 2013;36:2508–15. 23. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.

Download PDF sample

Rated 4.76 of 5 – based on 38 votes